Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Average Price Target of $60.00 According to Brokerages

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $60.00.

Several equities research analysts recently issued reports on AVLN shares. Weiss Ratings initiated coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating for the company. Morgan Stanley boosted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Finally, Raymond James Financial began coverage on Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 target price on the stock.

Avalyn Pharma Stock Performance

NASDAQ AVLN opened at $25.63 on Monday. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.14 billion and a P/E ratio of -1.12. Avalyn Pharma has a 52-week low of $22.24 and a 52-week high of $40.17. The company’s 50 day simple moving average is $30.16.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. On average, analysts forecast that Avalyn Pharma will post -3.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalyn Pharma

Several hedge funds have recently made changes to their positions in AVLN. China Universal Asset Management Co. Ltd. acquired a new stake in Avalyn Pharma in the third quarter valued at about $29,000. Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma in the 3rd quarter valued at approximately $36,000. Profund Advisors LLC purchased a new stake in shares of Avalyn Pharma in the third quarter valued at approximately $668,000. Bank of New York Mellon Corp acquired a new position in Avalyn Pharma during the second quarter worth $1,321,000. Finally, State Street Corp acquired a new position in Avalyn Pharma during the second quarter worth $10,501,000.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.